remdesivir

This is an April 30, 2020, file photo showing Gilead Sciences headquarters in Foster City, Calif.
Ben Margot/AP Photo, File
AP News
June 29, 2020 - 12:55 pm
The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.
Read More
Secretary of Health Dr. Rachel Levine speaking to reporters.
The Office of Governor Tom Wolf via Flickr
KYW Staff
May 13, 2020 - 5:28 pm
Pennsylvania has received its first shipment of remdesivir — the drug being used to treat COVID-19 patients — from the federal government. Read more here.
Read More
A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States.
Gilead Sciences via AP
AP News
April 29, 2020 - 11:25 am
A biotech company says its experimental drug has proved effective against the new coronavirus in a major U.S. government study that put it to a strict test. Read more here.
Read More
Lab technician doing research
appledesign/Getty Images
Mike Dougherty
April 18, 2020 - 11:56 am
Researchers around the world have taken an all hands approach to understanding the coronavirus, and the people at Penn Medicine are working on several clinical trials and studies. Read more here.
Read More
A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States.
Gilead Sciences via AP
AP News
April 06, 2020 - 11:34 am
Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks. Read more here.
Read More
coronavirus outbreak
iStock / Getty Images Plus
Tim Jimenez
February 26, 2020 - 7:22 am
The first U.S. study of a drug to treat the novel coronavirus is underway, the National Institutes of Health said Tuesday, as a federal health official warned that the virus will eventually begin spreading in the U.S. Read more here.
Read More